AgingResearch.NewsJoin free

Cyclarity Therapeutics

CompanyUnited States

Cyclarity Therapeutics develops one asset, in phase 1 (UDP-003 in atherosclerosis). Mostly small molecule; based in the United States.

1
Asset
Furthest stage
Phase 1
Raised
US$20.3m
0
Trials
0
Signals

Pipeline

1

  • UDP-003

    Captures and removes toxic oxidized cholesterol to restore macrophage function and reduce arterial plaque.

    Phase 1, Small molecule, atherosclerosis, neurodegenerative disease

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Funding rounds and grants2
  • People2
  • Similar companies6

Intelligence